Kidney Cancer

Elizabeth Plimack, MD, MS, discussed the depth of response for patients included in the KEYNOTE-426 trial investigating axitinib and pembrolizumab over sunitinib for patients with advanced renal cell carcinoma.

The Seattle Cancer Care Alliance Expert offered background on the first-line use of pembrolizumab monotherapy in advanced clear cell renal cell carcinoma.

Elizabeth Plimack, MD, MS, discussed the analysis of risk categories for patients included in the KEYNOTYE-426 trial investigating axitinib and pembrolizumab over sunitinib for patients with advanced renal cell carcinoma.

Elizabeth Plimack, MD, MS, discussed the role of subsequent immunotherapy when analyzing the primary endpoint of overall survival for axitinib and pembrolizumab over sunitinib in patients with advanced renal cell carcinoma evaluated in the updated analysis of KEYNOTE-426.

The VEGF TKI induced durable responses and favorable tolerability in patients with relapsed/refractory RCC.

In a webinar, a multidisciplinary team from Duke Cancer Center came together to discuss the differences in treating patients with genitourinary cancer as a result of the COVID-19 pandemic.

A recent study examined pancreatic metastases to understand why patients with this particular kidney cancer have better prognoses, and sought to characterize the clinical behavior, therapeutic implications, and underlying biology of this type of cancer.

The trial evaluated nivolumab in combination with cabozantinib compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma, meeting its primary endpoint of progression-free survival at final analysis.

A study showed that adolescents and young adults with certain types of cancers saw significant improvements in their 5-year mortality rates, while other cancer types saw little to no significant improvement among the same demographic group.

The biologics license application was supported by findings from a global, randomized, controlled phase III clinical trial, evaluating the efficacy, safety, and immunogenicity of MYL-1402O versus bevacizumab.

The findings reported in this study demonstrated a core dependency on HIF-2 in metastatic clear cell renal cell carcinoma and established PT2385 as a highly specific HIF-2 inhibitor.

The aim of this Chinese study was to evaluate the influencing factors of perioperative renal function change and their relationship with prognosis in patients with renal cell carcinoma and tumor thrombus after nephrectomy and thrombectomy.

Researchers indicated that a lack of understanding of the mechanism and efficacy of PD-1/PD-L1 inhibitors is the major barrier for prescription of these inhibitors in Chinese tumor treatment-related departments.

In this study, researchers looked at the adoption and use of bevacizumab in order to identify opportunities to increase use of high-value therapies.

Though physical activity guidelines are largely based on chronic diseases like cardiovascular disease and diabetes, these data suggest they are important to cancer prevention as well.

The Food and Drug Administration approved the first generic for everolimus, which can provide a safe, effective, lower cost alternative to the brand-name drug it references.

The next gen innovator discusses the integration of fields at the International Kidney Cancer Symposium in Miami.

The medical oncologist discusses the different talks that were presented at the International Kidney Cancer Symposium in Miami.

Treatment with lenvatinib and pembrolizumab has shown promise in patients with metastatic clear cell renal cell carcinoma who have already received an immune checkpoint inhibitor.

Massachusetts General Hospital’s Severe Immunotherapy Complications Service focuses on the increasing number of “rare” cases of immunotherapy-related adverse events.

New trial results examine whether there's a drug superior to sorafenib when it comes to treating kidney cancer.

Laparoscopic treatment during pregnancy is becoming an option for more women.

A new study looked at targeted vs nontargeted therapy in real world patients with renal cell carcinoma.

Nivolumab had limited efficacy against previously untreated brain metastases in patients with metastatic renal cell carcinoma, according to recent trial results.

An interim analysis of the CheckMate 920 phase IIIb/IV trial evaluated nivolumab plus ipilimumab in advanced renal cell carcinoma patients with brain metastases.

Cancer Network spoke with Daniel George, MD, of Duke Health, about the treatment landscape and current trials for renal cell carcinoma.

The KEYNOTE-426 study evaluated pembrolizumab plus axitinib vs sunitinib in patients with metastatic RCC with intermediate/poor risk disease and those with sarcomatoid features.

In this randomized phase III trial, researchers compared cytoreductive nephrectomy vs sunitinib alone in patients with metastatic renal cell carcinoma.

The phase II IMmotion150 study evaluated disease- and treatment-related symptoms in RCC patients receiving atezolizumab alone or in combination with bevacizumab vs sunitinib.

Findings from a planned subanalysis of IMmotion151 looked at combination atezolizumab and bevacizumab in patients with RCC and sarcomatoid histology.